Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies
暂无分享,去创建一个
I. Flinn | Hua Yang | R. Levine | M. Tallman | R. Stone | A. Fathi | D. Schenkein | D. Pollyea | S. Agresta | S. Botton | E. Stein | K. Yen | Bin Fan